.png?1623216833631)
\Involved pharmaceutical companies in the Hemorrhoids market are Nivagen Pharmaceuticals Inc. Edesa Biotech, Citius Pharmaceuticals, and others.
DelveInsight’s Hemorrhoids Pipeline report highlights the details around Hemorrhoids, which are swollen and inflamed veins around the anus or in the lower rectum. The Hemorrhoids report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Hemorrhoids report also highlights the unmet needs concerning the development of Hemorrhoids.
Some of the key highlights of the Hemorrhoids Pipeline report–
- Nivagen Pharmaceuticals Inc. initiated a randomized, double-blind, placebo-controlled, multicenter, parallel-group study of the safety and efficacy of Hydrocortisone Acetate Suppositories, 25 mg compared to placebo suppositories in the treatment of symptomatic internal hemorrhoids.
- Citius Pharmaceutical is developing its proprietary topical formulation of hydrocortisone (3%) and lidocaine (5%) to provide anti-inflammatory and anesthetic relief to patients suffering from Grade I and II hemorrhoids.
- Key companies involved in the Hemorrhoids Pipeline are Nivagen Pharmaceuticals Inc., Edesa Biotech, Citius Pharmaceuticals, and others.
Request for Sample @ Hemorrhoids Pipeline Insights
Hemorrhoids, also called piles, are swollen and inflamed veins around the anus or in the lower rectum. The two types of hemorrhoids are external hemorrhoids, which form under the skin around the anus, and internal hemorrhoids, which form in the lining of the anus and lower rectum.
Hemorrhoids Pipeline Emerging Therapies: Drug Profile
- Hydrocortisone Acetate Suppository: Nivagen Pharmaceuticals Inc.
Nivagen is engaged in the development, acquisition, and sales of generic prescription drugs and over-the-counter products across the globe.
- lidocaine: Citius Pharmaceuticals
Citius Pharmaceuticals threw the light by stating that although there are numerous prescription and over-the-counter (OTC) products commonly used to treat hemorrhoids, none currently possess safety and efficacy data generated from rigorously conducted clinical trials. It is currently in the phase II stage of development.
Know More Information @ Hemorrhoids Pipeline Drugs
Key Pipeline Therapies along with companies
- Hydrocortisone Acetate Suppository: Nivagen Pharmaceuticals Inc.
- EB02: Edesa Biotech
- 10.1.Halobetasol/lidocaine: Citius Pharmaceuticals
Hemorrhoids Therapeutics Assessment
By Product Type
- Mono
- Combination
By Stage
- Discovery
- Pre-clinical
- IND
- Phase I
- Phase II
- Phase III
- Pre-registration
By Route of Administration
- Intravenous
- Inhalation
- Oral
- Subcutaneous
By Molecule Type
- Small Molecule
- Gene Therapy
- Stem Cell Therapy
By Mechanism of Action
- Protease Inhibitors
- Immunomodulatory
By Targets
- Protease
- Immune System
Contact Here for More Information @ Hemorrhoids Pipeline Assessment
Scope of the Hemorrhoids Report
- Coverage- Global
- Key Market Players- Nivagen Pharmaceuticals Inc. Edesa Biotech, Citius Pharmaceuticals, and others.
- Key Hemorrhoids Pipeline Therapies:- Hydrocortisone Acetate Suppository, EB02, Lidocaine, and others
Table of Content
| 1 | Report Introduction |
| 2 | Hemorrhoids |
| 3 | Hemorrhoids Current Treatment Patterns |
| 4 | Hemorrhoids – DelveInsight’s Analytical Perspective |
| 5 | Therapeutic Assessment |
| 6 | Hemorrhoids Late Stage Products (Phase-III) |
| 7 | Hemorrhoids Mid Stage Products (Phase-II) |
| 8 | Early Stage Products (Phase-I) |
| 9 | Pre-clinical Products and Discovery Stage Products |
| 10 | Inactive Products |
| 11 | Dormant Products |
| 12 | Hemorrhoids Discontinued Products |
| 13 | Hemorrhoids Product Profiles |
| 14 | Hemorrhoids Key Companies |
| 15 | Hemorrhoids Key Products |
| 16 | Dormant and Discontinued Products |
| 17 | Hemorrhoids Unmet Needs |
| 18 | Hemorrhoids Future Perspectives |
| 19 | Hemorrhoids Analyst Review |
| 20 | Appendix |
| 21 | Report Methodology |
Know more of what’s covered in the Hemorrhoids Pipeline Assessment report
Key Questions Answered in the Hemorrhoids report-
- What are the current options for Hemorrhoids treatment?
- How many companies are developing therapies for the treatment of Hemorrhoids?
- What are the principal therapies developed by these companies in the industry?
- How many therapies are developed by each company for the treatment of Hemorrhoids?
- How many Hemorrhoids emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Hemorrhoids?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Hemorrhoids market?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies for the treatment of Hemorrhoids?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Hemorrhoids therapies?
- What are the clinical studies going on for Hemorrhoids and their status?
- What are the results of the clinical studies and their safety and efficacy?
- What are the key designations that have been granted for the emerging therapies for Hemorrhoids?
- How many patents are granted and pending for the emerging therapies for the treatment of Hemorrhoids?
Request for demo @ Hemorrhoids Pipeline and get a walk-through of our report
Related Reports
DelveInsight’ s Hemorrhoids Market Insights, Epidemiology and Market Forecast 2030 report.
DelveInsight’s Hemorrhoids – Epidemiology Forecast 2030 report.
DelveInsight’ s Crohn’s Disease Market Insights, Epidemiology and Market Forecast – 2030 report
Crohn’s Disease Pipeline Insights, 2021 report
DelveInsight’ s Ulcerative Colitis Market Insights, Epidemiology and Market Forecast 2030 report.
Ulcerative Colitis Pipeline Insights, 2021 report.
DelveInsight’ s Colorectal Cancer Market Insights, Epidemiology and Market Forecast 2030 report.
Colorectal Cancer Pipeline Insights, 2021 report.
DelveInsight’ s Anal Cancer Market Insights, Epidemiology and Market Forecast – 2030
Anal Cancer Pipeline Insights, 2021 report
Visit on our blog section-
- Companies In Digestive Disorders Market
- Roche’s Oral SMA Therapy; Roche’s Etrolizumab
- Colorectal Cancer Market Analysis and Market Forecast
- Top Five Prevalent Cancers in the World
About DelveInsight
DelveInsight is a leading Business Consultant & Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare & pharma market research reports through our subscription-based platform PharmDelve.
Contact Information:
Shruti Thakur info@delveinsight.com +1(919)321-6187
Tags:
, Reportedtimes, IPS, Menafn, Extended Distribution, iCN Internal Distribution, Research Newswire, English
Contact Information:
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
The post Hemorrhoids Pipeline Analysis: Key Pharma Players Set to Develop Innovative Therapies and Explore Innumerable Opportunities. appeared first on Financial Market Brief.